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COMMeNTary
The NAD-synthesizing enzyme NMNAT2 is critical for axon sur-
vival in primary culture and its depletion 
may contribute to axon degeneration in 
a variety of neurodegenerative disorders. 
Here we discuss several recent reports 
from our laboratory that establish a criti-
cal role for NMNAT2 in axon growth in 
vivo in mice and shed light on the deliv-
ery and turnover of this survival factor 
in axons. In the absence of NMNAT2, 
axons fail to extend more than a short 
distance beyond the cell body dur-
ing embryonic development, implying 
a requirement for NMNAT2 in axon 
maintenance even during development. 
Furthermore, we highlight findings 
regarding the bidirectional trafficking of 
NMNAT2 in axons on a vesicle popula-
tion that undergoes fast axonal transport 
in primary culture neurites and in mouse 
sciatic nerve axons in vivo. Surprisingly, 
loss of vesicle association boosts the axon 
protective capacity of NMNAT2, an 
effect that is at least partially mediated 
by a longer protein half-life of cytosolic 
NMNAT2 variants. Analysis of wild-
type and variant NMNAT2 in mouse 
sciatic nerves and Drosophila olfactory 
receptor neuron axons supports the exis-
tence of a similar mechanism in vivo, 
highlighting the potential for regulation 
of NMNAT2 stability and turnover as a 
mechanism to modulate axon degenera-
tion in vivo.
Introduction
Axon pathology is a major contributor 
to nervous system dysfunction in many 
neurodegenerative diseases. Indeed, axo-
nal dysfunction, and an impairment of 
axonal transport in particular, are often 
observed at very early stages of disease 
before the onset of symptoms and before 
widespread neurodegeneration. This sug-
gests a potential causative role of axonal 
impairments for the resulting neurodegen-
eration.1-3 The spontaneous mutant WldS 
mouse, in which the degeneration of an 
axon distal to a site of injury (Wallerian 
degeneration) is delayed significantly, has 
helped establish the concept that axon 
degeneration in many neurodegenerative 
conditions is mechanistically related to 
Wallerian degeneration.4 The WldS gene is 
a chimera that arises from a triplication on 
mouse chromosome four5 and consists of 
the coding sequence for the N-terminal 70 
amino acids of the ubiquitin conjugation 
factor Ube4b fused, via an 18 amino acid 
linker, to the full coding region of Nmnat1 
(Nicotinamide mononucleotide adeny-
lyltransferase 1).6 Expression of this chi-
meric protein in mice,6 rats,7 zebrafish,8,9 
Drosophila10,11 or in human dorsal root 
ganglion neurons in primary cutlture12 
is sufficient for the WLDS phenotype of 
delayed Wallerian degeneration.
Even though initially only detected in 
the nucleus,13 recent results show that the 
WLDS protein is also present in axons in 
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vivo.14 Moreover, its exclusion from the 
nucleus, and the resulting stronger accu-
mulation in the cytoplasm, increases its 
protective properties, suggesting a non-
nuclear site of action.14 Recent work in our 
laboratory established NMNAT2, which 
shares its NAD-synthesizing enzymatic 
activity with the WLDS fusion protein, 
as a critical survival factor that prevents 
spontaneous degeneration in primary cul-
ture neurites. Its constant supply from the 
cell body into axons is required for axon 
survival and its rapid depletion after a 
block of axonal transport appears to be 
sufficient to trigger Wallerian degenera-
tion.15 Due to its very short half-life, any 
disruption in NMNAT2 axonal transport 
could result in spontaneous axon degen-
eration. Indeed, the ability of WLDS to 
protect against axon degeneration in sev-
eral neurodegenerative disease models 
suggests that a relative lack of NMNAT2 
supply could contribute to axon degenera-
tion in these conditions, though the role of 
NMNAT2 in disease remains to be tested 
(see Fig. 1).15 Based on these findings, it is 
important to understand the axonal traf-
ficking of the endogenous survival factor 
NMNAT2, its role in axon maintenance 
in vivo, as well as the factors that deter-
mine its turnover and axon protective 
capacity.
Role of NMNAT2 for Axon 
Maintenance in Vivo
In order to confirm the importance of 
NMNAT2 for axon survival in vivo, we 
generated conditional Nmnat2 gene trap 
mice, similar to the NMNAT2-deficient 
Blad mutant mice recently described.16 
Homozygous Nmnat2gtE/gtE mice lacked 
any detectable NMNAT2 expres-
sion. Consistent with a requirement for 
NMNAT2 for axon survival in vivo, axons 
in both peripheral and central nervous 
systems were truncated at short distances 
beyond the cell body.17 While analysis of 
the Blad mutant mice led to the sugges-
tion of a degenerative axon defect in the 
absence of NMNAT2, our data indicate 
an early developmental defect in axon 
extension instead. The inability to detect 
degenerated fragments of distal axons, 
together with repeated imaging of pri-
mary culture neurite outgrowth, suggest 
that these axons never extended more than 
a few millimeters beyond the cell body.17 
This indicates that NMNAT2 is required 
during development and axons fail to grow 
normally in its absence. The short axon 
stumps that were supported in this condi-
tion were most likely maintained by the 
presence of NMNAT1, whose enzymatic 
activity is localized within the nucleus. 
Exchange of NAD and related metabo-
lites between the proximal axon and cell 
body through simple diffusion could thus 
support the limited axon extension found 
in the absence of NMNAT2. In further 
support of an NMNAT-dependent axon 
maintenance model, gross morphologi-
cal defects as well as the truncation of 
peripheral and central nervous system 
axons in Nmnat2gtE/gtE mice were rescued 
by expression WLDS in a dose-dependent 
manner, with WLDS homozygotes surviv-
ing even into adulthood.17 This confirms 
the ability of WLDS to directly substitute 
for NMNAT2 in both axon growth and 
maintenance in vivo.
The above findings imply a novel 
developmental role for NMNAT2. 
However, it is conceivable that the mecha-
nism that limits axon outgrowth in the 
absence of NMNAT2 is closely related 
to the axon degeneration pathway trig-
gered by depletion of NMNAT2 after 
axotomy or disruption of axonal trans-
port. If NMNAT2 levels are critical for 
axon maintenance from the outset, axons 
extending beyond a threshold distance 
where NMNAT2 levels become limiting 
for axon survival may degenerate at their 
distal extremities.
Given the short half-life and critical 
role of NMNAT2 in axon maintenance, 
any reduction in NMNAT2 supply could 
put axons at risk of degeneration.15 The 
well-documented reduction in axonal 
transport during aging18 and disease-asso-
ciated disruptions to axonal transport2 
could thus synergize to deplete NMNAT2 
in distal axons sufficiently to induce axon 
degeneration. In agreement with such 
a model, loss of NMNAT2 expression 
from one allele (resulting in a maximum 
50% decrease in protein expression) was 
sufficient to deplete NMNAT2 below its 
critical threshold and induce spontaneous 
axon degeneration.17
Interestingly, however, our data also 
indicate that axons can undergo com-
pensatory changes that allow them to 
grow and survive in the presence of oth-
erwise sub-threshold levels of NMNAT2. 
Compound heterozygotes carrying two 
independent NMNAT2 knockdown 
alleles express approximately 25% of wild-
type levels of NMNAT2, well below the 
50% level at which we observed sponta-
neous degeneration after loss of expression 
from one allele. Interestingly, however, 
these compound heterozygous mice are 
overtly normal, fertile and live until at least 
12 months of age.17 This surprising result 
indicates that downstream elements of the 
axon degeneration pathway can, to some 
degree, adapt to lower levels of NMNAT2 
and maintain axon integrity in a situation 
where such low levels of NMNAT2 are 
present from early development onwards. 
Identification of the mechanism(s) 
responsible for these compensatory 
changes could open up novel avenues to 
delay axon degeneration when NMNAT2 
supply is limited through impairments of 
axonal transport. In particular, it will be 
important to determine if these changes 
can be induced in mature axons to allow 
axon survival at what would otherwise be 
sub-threshold NMNAT2 levels.
Axonal Trafficking  
and Turnover of NMNAT2
Previously, NMNAT2 was shown to 
associate with the Golgi apparatus in 
HeLa cells and this association depends 
on an intact C164/C165 dual-cysteine 
palmitoylation site in its central ISTID 
(isoform specific targeting and interac-
tion) domain.19,20 Additionally, NMNAT2 
was seen to traffic bidirectionally along 
primary culture neurites on particles and 
at speeds compatible with fast axonal 
transport.15 In one recent report, we con-
firmed the vesicular nature of this trans-
port organelle by showing co-migration of 
NMNAT2 with Golgi and synaptic ves-
icle markers, suggesting a Golgi-derived 
vesicle population as the mode of entry 
for NMNAT2 into axons. Additionally, 
we confirmed that the C164/165 palmi-
toylation site was required for vesicular 
axonal transport of NMNAT2.21 Based 
on the known short half-life of NMNAT2 
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and its critical role in axon mainte-
nance, we envisaged a model in which a 
vesicle-bound population of NMNAT2 
would be shielded from turnover dur-
ing transport, as it takes many hours or 
even days to reach the distal ends of long 
axons. Interestingly, we found the oppo-
site to be the case. Cytosolic NMNAT2 
mutants lacking palmitoylation and 
Figure 1. Model of NMNaT2 depletion as a trigger of Wallerian degeneration and axon protection by WLDS. In a healthy axon, NMNaT2 is rapidly turned 
over by the ubiquitin proteasome system (UPS). In order to carry out its enzymatic function, the conversion of NMN to NaD, it is constantly replenished 
from the cell body by axonal transport. axonal transport can be blocked or reduced through injury of the axon, through disease processes that affect 
the efficiency of transport or during normal aging. Due to its short half-life, NMNaT2 is rapidly depleted distally to a site of injury or block of axonal 
transport. The resulting lack of the critical NMNaT enzyme activity triggers a downstream signaling cascade culminating in Wallerian degeneration. as 
WLDS has a much longer half-life than NMNaT2, and as these two proteins share the same enzymatic activity, WLDS, if present in the axon, can substitute 
the critical enzyme activity after depletion of NMNaT2, resulting in a significantly prolonged latent phase of degeneration.
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vesicle association had a longer protein 
half-life than the vesicle-bound, wild-type 
form.21 Similarly, fluorescently tagged 
NMNAT2-Venus in mouse peripheral 
nerves in vivo was stabilized signifi-
cantly after loss of central ISTID regions 
that mediate vesicle attachment.22 The 
observed increase in half-life was at least 
partially mediated by reduced levels of 
ubiquitination of the cytosolic forms and 
resulted in an improved level of axon pro-
tection by these mutants in primary cul-
ture neurites. Importantly, these changes 
were reverted when cytosolic mutants 
were re-targeted to vesicle membranes 
by various means, indicating that asso-
ciation with vesicle membranes promotes 
NMNAT2 ubiquitination and turnover.21 
Given that we found palmitoylation to be 
critical for NMNAT2 membrane associa-
tion, the enzymes mediating NMNAT2 
palmitoylation and, potentially, depal-
mitoylation may thus be of interest when 
trying to modulate NMNAT2 subcellular 
localization and turnover.
The precise mechanism behind the ele-
vated ubiquitination of vesicle-associated 
NMNAT2 is as yet unclear. However, one 
interesting possibility is the localization of 
a relevant ubiquitin ligase enzyme to the 
NMNAT2 transport vesicle (see Figure 2). 
In support of this idea, we found that re-
targeting cytosolic NMNAT2 mutants to 
the mitochondrial outer membrane did 
not induce NMNAT2 ubiquitination, 
suggesting a mechanism that is specific 
for vesicle membranes.21
Figure 2. Model of the mechanism of vesicle association–induced ubiquitination and turnover of NMNaT2. Palmitoylation promotes membrane asso-
ciation of NMNaT2, thus bringing it into close proximity with Phr1 and/or other putative e3 ubiquitin ligases. The close association and confinement to 
a 2D space strongly promote NMNaT2 K48-linked poly-ubiquitination and rapid turnover by the proteasome. Thus, NMNaT2 half-life is short, resulting 
in rapid depletion after axotomy or interruption of axonal transport and, ultimately, rapid axon degeneration. In contrast, cytosolic NMNaT2 encounters 
relevant e3 ubiquitin ligases much less frequently, resulting in lower levels of K48-linked poly-ubiquitination and a slower rate of UPS-mediated turn-
over. Consequently, the half-life of cytosolic NMNaT2 is prolonged, resulting in a longer latent phase and delayed axon degeneration.
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Effects of palmitoylation on the rate of 
turnover have been reported for several tar-
get proteins, including cell surface recep-
tors,23-26 the oncogene TBC1D3,27 the 
intracellular trafficking protein Sortilin28 
and the S. cerevisiae Tlg1 SNARE pro-
tein.29 For all these, palmitoylation 
appears to result in stabilization of the 
target protein, in contrast to our findings 
regarding NMNAT2. The effects on pro-
tein stability in the above cases appear to 
be mediated by palmitoylation-dependent 
regulation of the relative subcellular local-
ization of target proteins with respect to 
their relevant E3 ubiquitin ligases, effec-
tively limiting the accessibility of target 
proteins to ubiquitin ligases. It is possible 
that a converse mechanism operates for 
NMNAT2, such that instead of shield-
ing it from ubiquitination, palmitoylation 
could place NMNAT2 in the proximity of 
its E3 ubiquitin ligase.
Interestingly, a candidate E3 ubiquitin 
ligase for NMNAT2 has recently been 
identified. First, Drosophila dNmnat was 
characterized as a target of the E3 ligase 
Highwire. In the absence of Highwire 
both dNmnat and ectopically expressed 
mammalian NMNAT2 were more stable 
in axons, and axons were preserved sig-
nificantly longer after axotomy.30 Another 
study then reported delayed axon degen-
eration in conditional knockout mice 
for Phr1 (MYCBP2), the murine homo-
log of Highwire. Steady-state levels of 
NMNAT2 were elevated in these mice 
and this increase in NMNAT2 levels was 
necessary for axon protection.31 Together, 
these findings establish Phr1 as a candi-
date E3 ubiquitin ligase for NMNAT2. 
Interestingly, Phr1 was also identified in 
a proteomics analysis performed on dif-
ferent classes of axonal transport vesicles 
and found to associate with a specific sub-
population of vesicles.32 These data are 
consistent with a model in which palmi-
toylation and vesicle association promote 
NMNAT2 ubiquitination and turnover 
by bringing it into proximity with Phr1 
and, perhaps, other relevant E3 ubiquitin 
ligases on axonal transport vesicle mem-
branes (Fig. 2).
Axon protection in the absence of can-
didate E3 ubiquitin ligases for dNmnat/
NMNAT2,30,31 the delay of axon degen-
eration in the presence of inhibitors of the 
ubiquitin-proteasome system33 (UPS) and 
our findings regarding the localization-
dependent turnover and axon protective 
capacity of NMNAT221,22 all support 
NMNAT2 protein stability as a promising 
target for modulating axon degeneration. 
The most useful step for intervention in 
NMNAT2 ubiquitination and turnover 
remains to be determined. However, tar-
geting the UPS as a whole is unlikely to be 
advantageous as long-term inhibition and 
dysfunction of the UPS actually contribute 
to neurodegenerative disease.34 Similarly, 
interference with E3 ligases might be dif-
ficult, especially given the critical roles of 
Phr1 during development35-38 and its other 
identified downstream targets.39-41 Thus, 
modulation of NMNAT2 subcellular 
localization, perhaps through interference 
in its palmitoylation status, could be an 
interesting alternative.
We found that loss of exon 6-encoded 
central ISTID sequences boosted 
NMNAT2 protective capacity both in 
mouse primary culture neurites and in 
Drosophila axons in vivo. Interestingly, 
the degree of protection, at least in pri-
mary culture, was stronger than that 
achieved by expression of WLDS.21,22 This 
finding illustrates that the survival fac-
tor NMNAT2, normally an endogenous, 
labile protein that is rapidly lost after its 
supply from the cell body ceases, can be 
changed into a highly axon protective 
molecule.
The mechanism by which loss of the 
central ISTID region mediates this strong 
increase in protective capacity remains to 
be elucidated. Interestingly, the central 
ISTID-deficient protein was no more sta-
ble than a simple exon 6 point mutant, at 
least in HEK 293T cells, suggesting that 
mechanisms other than protein stability, 
such as an altered enzymatic activity or 
protein-protein interactions, may mediate 
this change.21 On the other hand, protein 
turnover mechanisms could differ in the 
axon. In agreement with this, proteasome 
inhibition only partially arrests NMNAT2 
turnover in primary culture neurites but 
completely stops it in HEK 293T cells.15 
Similarly, the continued turnover of 
NMNAT2 in the absence of Phr131 could 
point to an alternative, non-UPS route that 
partially mediates NMNAT2 degradation 
(or, of course, to the presence of additional 
E3 ubiquitin ligases targeting NMNAT2, 
which remain to be identified). Thus, the 
central ISTID sequence could be involved 
in such a putative, alternative pathway for 
NMNAT2 turnover in axons. Given the 
strong effects of loss of the central ISTID 
region on its axon protective capacity, it 
will be very interesting to elucidate the 
underlying mechanism.
Interestingly, existing data could be 
interpreted to suggest that NMNAT2 does 
not need to be present in the axon indefi-
nitely to delay Wallerian degeneration. In 
our transgenic mice, levels of NMNAT2-
Venus protein fall significantly by 72 h 
after cut, yet axons are very strongly pro-
tected up to 14 d after cut.22 As above, the 
continued turnover of NMNAT2 in the 
absence of Phr1 is a similar example—
NMNAT2 is still lost fairly rapidly after 
axotomy in neurites deficient of Phr1, yet 
axons are protected for prolonged periods 
of time in vivo.31 These findings could 
suggest that NMNAT enzymatic activity 
only needs to be present in the axon dur-
ing the initial phase after axotomy. If this 
is the case, it might imply that one or more 
downstream executors of the axon degen-
eration pathway are also unstable and 
undergo rapid turnover within the first 
few hours after cut. As long as a sufficient, 
above-threshold amount of NMNAT2 
“outlasts” them, protection could be 
achieved. Although not an executor mol-
ecule, the recent finding that the rate of 
turnover of SCG10 influences the progres-
sion of Wallerian degeneration42 supports 
the idea that relative levels and stabilities 
of both positive and negative regulators 
of the axon degeneration pathway could 
be critical in determining the duration 
of axon survival. Alternatively, protein 
turnover may slow down sufficiently after 
cut so that the higher starting levels of 
NMNAT2 in the above situations mean 
that sufficient quantities remain in the 
axon at later times to ensure axon survival.
Open Questions
One of the main questions arising from 
our model is how neurons are able to sup-
ply sufficient quantities of extremely labile 
NMNAT2 into axons to avoid spontane-
ous axon degeneration. With a half-life of 
around 45 min,21 the velocity of fast axonal 
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transport means that a fraction of less 
than 1% of all NMNAT2 would arrive at 
the distal end of a moderately long, 4 cm 
mouse peripheral axon. The scale of the 
problem becomes massive in a long human 
peripheral nerve of one meter length, with 
fast axonal transport taking several days to 
arrive at the distal end. Importantly, the 
half-life of human NMNAT2 has not yet 
been assessed and could differ from that 
of mouse NMNAT2 in order to support 
much longer axons and the resulting lon-
ger transport times in human peripheral 
nerves. However, this appears unlikely as 
there is very high sequence conservation 
and we found human NMNAT2 to be no 
more protective than mouse NMNAT2 
against neurite degeneration after axot-
omy when expressed in mouse primary 
culture neurites.21 Additionally, human 
dorsal root ganglion neurites degenerate 
within 5 h after cut in primary culture,12 
further arguing against a longer half-
life of human NMNAT2. Perhaps more 
likely, the half-life of NMNAT2 could 
be different in axons in vivo as compared 
with primary culture neurites. Indeed, the 
longer latent phase of Wallerian degenera-
tion in vivo supports this idea and suggests 
that NMNAT2 could be more stable and 
require a longer time to be depleted suf-
ficiently after axotomy to trigger degen-
eration. Currently, in the absence of 
suitable antibodies, there is no data that 
we are aware of that would support this 
claim. Our findings regarding turnover of 
NMNAT2-Venus in sciatic nerves do not 
adequately address this issue either, as we 
have shown that the YFP Venus tag most 
likely stabilizes the protein.22 If NMNAT2 
is indeed more stable in vivo, the relevant 
mechanisms remain to be elucidated, but 
the presence of non-neuronal cells is one 
potential factor that could contribute to 
this effect.
Another possibility that has not been 
explored in-depth so far is that NMNAT2 
turnover might accelerate in axons after 
cut. Such a longer half-life in uninjured 
axons would allow sufficient quantities 
of NMNAT2 to reach the distal ends of 
intact axons to ensure axon maintenance. 
Alternatively, palmitoylation could target 
NMNAT2 to multiple vesicle popula-
tions with distinct effects on its half-life, 
as other cargoes have been shown to 
associate with multiple vesicle popula-
tions with only partially overlapping sets 
of associated proteins.32 One could envis-
age a system in which one class of vesicles 
delivers NMNAT2 into the axon without 
reducing its half-life (e.g., a Phr1-deficient 
vesicle population), while association 
with another class of vesicles (e.g., a Phr1-
containing vesicle population) could 
promote its removal from the cytosol, 
ubiquitination and turnover. Elucidating 
the precise identity of vesicle sub-popula-
tions that NMNAT2 associates with and 
perhaps the identification of alternative 
E3 ubiquitin ligases or of ubiquitin–prote-
asome independent turnover pathways for 
NMNAT2 will help answer the question 
of how NMNAT2 is turned over and how 
healthy axons ensure a sufficient supply to 
prevent spontaneous degeneration.
It is worth noting that local synthesis 
of NMNAT2 in the axon seems unlikely 
to contribute significantly to its replen-
ishment. Several large-scale studies iden-
tified hundreds of axonal mRNAs, but 
Nmnat2 mRNA was not found,43-46 sug-
gesting that, at least in primary culture 
neurites, it is either absent from axons or 
present at very low, sub-detection abun-
dance. Moreover, cell body but not axonal 
protein synthesis is required for axon sur-
vival,15 suggesting that most NMNAT2 
is supplied by the cell body. Additionally, 
the inability of isolated axons to maintain 
a sufficient supply of NMNAT2 to ensure 
axon survival after axotomy does of course 
in itself argue against a substantial contri-
bution of local synthesis to axonal levels of 
NMNAT2.
Another, related, “frequently asked 
question” is why NMNAT2 is so unstable 
in the first place. One possibility is that 
a stable cytoplasmic NMNAT enzyme in 
axons could have—so far uncharacter-
ized—adverse effects. The short half-life 
would then result from balancing this 
adverse effect with the risk of axon degen-
eration. However, the observation that 
mice expressing stable, axonally targeted 
NMNATs (such as WLDS, NMNAT2-
Venus and NMNAT2Δex6-Venus) are 
overtly healthy and normal until at least 
12 months of age suggests that there is no 
obvious adverse effect associated with the 
possession of a stable, cytosolic NMNAT 
enzyme in axons. Thus, a second, and 
perhaps more likely, possibility is that rapid 
turnover of NMNAT2 and the resulting 
fast Wallerian degeneration are beneficial. 
Peripheral nerve regeneration in many 
species of mammal is remarkably efficient 
and functional recovery is relatively quick, 
with obvious implications for the animal’s 
evolutionary fitness. As regeneration of 
peripheral nerve axons is impaired when 
degeneration is delayed,47-51 rapid degen-
eration probably facilitates rapid regenera-
tion and functional recovery in a situation 
of peripheral nerve injury where a distal 
stump that has been separated from the 
proximal axon and cell body is of no fur-
ther use. Unfortunately, peripheral nerve 
regeneration in humans is not as efficient 
as that observed in many other species of 
mammal.52 Additionally, Wallerian-like 
degeneration affects axons in the central 
nervous system, where spontaneous regen-
eration and functional recovery are rare 
and spatially limited. Thus, the problem 
from a human point of view is that this 
system puts axons at risk of degenera-
tion that are not irreversibly damaged. In 
situations where axonal transport is suffi-
ciently impaired, distal NMNAT2 levels 
could fall below critical levels, triggering 
the degeneration pathway in axons that 
are still continuous with their cell bod-
ies. Preventing this Wallerian-like degen-
eration in situations where maintenance of 
the existing axon is more beneficial than 
the attempt to regenerate a new one is 
likely to produce clinical benefits in many 
neurodegenerative conditions.
One area of clinical importance where 
this could apply is chemotherapy-induced 
peripheral neuropathy. Several chemo-
therapy drugs have been shown to impair 
axonal transport in vitro and in vivo.53-56 
Additionally, the ability of WLDS expres-
sion to prevent axon degeneration and 
peripheral neuropathy induced by pacli-
taxel in mice, and by vincristine in pri-
mary culture, suggests a Wallerian-like 
mechanism of axon degeneration.57-59 
Given our recent findings about the role 
of NMNAT2 in axon maintenance and 
the mechanism of axon protection by 
WLDS by substituting for NMNAT2,15 
one mechanism by which these micro-
tubule-targeting drugs cause peripheral 
neuropathy could be a reduced supply of 
NMNAT2 into distal axons. Modulation 
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of the axon survival factor NMNAT2 
through alterations to its half-life or axo-
nal delivery may be a promising route to 
address these issues.
Together these recent reports con-
firm important roles for endogenous 
NMNAT2 for axon growth and survival 
in vivo and show that variant NMNAT2 
forms that lack central ISTID sequences 
can preserve injured axons in mammalian 
primary culture and in vivo, both in mice 
and Drosophila, with an efficacy matching 
or even exceeding that of WLDS. These 
sequences seem to be closely linked to 
turnover of NMNAT2, which appears to 
involve vesicle targeting and ubiquitin-
proteasome mediated turnover. The E3 
ligase Highwire/Phr1 is a strong candidate 
for mediating this process at least par-
tially. Modulation of NMNAT2 subcel-
lular localization and turnover could thus 
present a novel avenue to address axon 
degeneration in situations of an impaired 
axonal supply of this critical axon survival 
factor.
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